Immune reconstitution syndrome-like entity in lung transplant recipients with invasive aspergillosis.

摘要: Abstract Background Incidence, characteristics, and risk-factors for invasive aspergillosis (IA)-associated immune reconstitution syndrome (IRS) in lung transplant recipients are not known. Methods Patients comprised 68 with proven/probable IA followed 12 months. IRS was defined based on previously proposed criteria. Results In all, 7.3% (5/68) of the patients developed aforementioned criteria, a median 56 days after initiation antifungal therapy. This entity associated heart–lung transplantation (p = 0.006), anti T-cell agent use (p = 0.003), discontinuation calcineurin inhibitor (p = 0.002), disseminated (p = 0.069). risk assessment model, 0% (0/55) none factors, 28.6% (2/7) one, 33.3% (1/3) two, 1/1 patient 3 factors (X2 trend p = 0.0001). Three out 5 died 2 deaths this group were due to chronic rejection. Conclusions Overall 7% appear develop an IRS-like entity. Clinically assessable can identify at post-transplant IA-associated IRS. Deaths rejection significantly higher than those without